CTS2016 was evaluated both as a single agent and in combination with venetoclax or azacitidine in various in vitro and in vivo AML models and has been reported to exhibit strong growth inhibition and induced cell death in AML cell lines with FLT3 mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.